In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum.

@article{Kim2008InVM,
  title={In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum.},
  author={Hee-yeon Kim and Soo Jin Oh and Se-keun Park and Guo-cheng Han and K Kim and Kye Sook Lee and Jong Soon Kang and M Nam},
  journal={Xenobiotica; the fate of foreign compounds in biological systems},
  year={2008},
  volume={38 3},
  pages={281-93}
}
1. The metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, was investigated in vitro using human liver microsomes and serum. After 60-min incubation in human liver microsomes with beta-nicotinamide adenine dinucleotide phosphate (NADPH) or uridine diphosphate glucuronic acid (UDPGA), the residual KBH-A40 was 90.6% +/- 5.1% and 28.9% +/- 2.0% (t(1/2) = 26 min), respectively, suggesting that KBH-A40 is likely predominantly metabolized by glucuronidation, rather… CONTINUE READING